Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Laboratorios Farmaceuticos Rovi, SA Stock , LABFF

39.51 EUR -0.35 -0.88%
Official Close 3/17/2023 STU
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar


Laboratorios Farmaceuticos Rovi Historical Prices

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Laboratorios Farmaceuticos Rovi Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell

Laboratorios Farmaceuticos Rovi Estimates* in EUR

  2023 2024 2025 2026
Revenue 729 798 869 1,063
Dividend 0.84 0.97 1.30 1.49
Dividend Yield (in %) 2.08 % 2.40 % 3.22 % 3.69 %
EPS 2.40 2.93 3.81 4.26
P/E Ratio 16.51 13.51 10.37 9.29
EBIT 152 188 232 303
EBITDA 185 222 267 331
Net Profit 122 152 188 230
Net Profit Adjusted 123 154 205 -
Pre-Tax Profit 152 188 217 303
Net Profit (Adjusted) 137 174 - -
EPS (Non-GAAP) ex. SOE - - - -
EPS (GAAP) 2.21 2.89 3.46 4.26
Gross Income 433 471 504 671
Cash Flow from Investing - - -53 -51
Cash Flow from Operations 166 184 240 -
Cash Flow from Financing - - -68 -73
Cash Flow per Share 2.49 3.25 3.95 -
Free Cash Flow 108 138 185 192
Free Cash Flow per Share 1.70 2.32 2.88 -
Book Value per Share 10.69 12.75 14.27 -
Net Debt -99 -195 -295 -
Research & Development Exp. 39 38 29 43
Capital Expenditure 35 28 29 51
Selling, General & Admin. Exp. 230 244 265 298
Shareholder’s Equity 577 685 812 1,126
Total Assets 865 972 1,146 1,447
  Previous Quarter
ending 12/31/22 		Current Quarter Next Quarter Current Year
ending 12/31/23 		Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts - - - 8 8
Average Estimate - - - 2.397 EUR 2.929 EUR
Year Ago - - - - 2.397 EUR
Publish Date - - - - -
Revenue Estimates
No. of Analysts 7 - - 8 8
Average Estimate 232 EUR - - 729 EUR 798 EUR
Year Ago - - - 818 EUR 729 EUR
Publish Date 2/21/2023 - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Laboratorios Farmaceuticos Rovi Dividend Calendar

Date Name Dividend *yield Currency
2022 Laboratorios Farmaceuticos Rovi, SA 1.05 2.91 EUR
2021 Laboratorios Farmaceuticos Rovi, SA 0.77 1.05 EUR
2020 Laboratorios Farmaceuticos Rovi, SA 0.31 0.81 EUR
2019 Laboratorios Farmaceuticos Rovi, SA 0.14 0.58 EUR
2018 Laboratorios Farmaceuticos Rovi, SA 0.06 0.37 EUR
2017 Laboratorios Farmaceuticos Rovi, SA 0.10 0.62 EUR
2016 Laboratorios Farmaceuticos Rovi, SA 0.15 1.20 EUR
2015 Laboratorios Farmaceuticos Rovi, SA 0.11 0.78 EUR
2014 Laboratorios Farmaceuticos Rovi, SA 0.14 1.31 EUR
2013 Laboratorios Farmaceuticos Rovi, SA 0.13 1.28 EUR
2012 Laboratorios Farmaceuticos Rovi, SA 0.11 2.04 EUR
2011 Laboratorios Farmaceuticos Rovi, SA 0.10 1.97 EUR
2010 Laboratorios Farmaceuticos Rovi, SA 0.14 2.90 EUR
2009 Laboratorios Farmaceuticos Rovi, SA 0.11 1.48 EUR
*Yield of the Respective Date

Laboratorios Farmaceuticos Rovi, SA Past Events

Event Actual EPS Info Date

Laboratorios Farmaceuticos Rovi Profile

Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
4
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Laboratorios Farmaceuticos Rovi Shareholder

Owner in %
Norbel Inversiones SL 55.19
Freefloat 38.36
Indumenta Pueri SL 5.25
T Rowe Price International Discovery Fund 2.06
Wellington Management Co. LLP 1.80
Government Pension Fund - Global (The) 1.54
Wellington Management International Ltd. 1.30
Laboratorios Farmaceúticos Rovi SA 1.19
RBC European Mid-Cap Equity Fund 0.81
Melchior Selected Trust - European Opportunities Fund 0.69
Arbarin, SICAV 0.66
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Laboratorios Farmaceuticos Rovi Management

Name Job
Juan López-Belmonte Encina Chairman, President & Chief Executive Officer
Marina del Corral Téllez Director
Javier López-Belmonte Encina First Vice Chairman & Chief Financial Officer
Aránzazu Lozano Pirrongelli Head-Internal Auditor
Marta Campos Martínez Head-Investor Relations
Fátima Báñez García Independent Director
Enrique Castellón Leal Independent Director
Teresa Corzo Santamaría Independent Director
Marcos Peña Pinto Lead Independent Director
Francisco Javier Ángulo García Manager-Human Resources
Miguel Angel Castillo Román Manager-International & Business Development
Mercedes Benitez del Castillo Sanchez Manager-Legal Department
Ibón Gutierro Adúriz Manager-Research & Development
Fernando Martínez Garijo Manager-Sales Effectiveness
M. Rosario Perucha Perez Marketing Manager
Beatriz Avila Alcalde Sales Manager
Iván López-Belmonte Encina Second Vice Chairman
Gabriel Núñez Fernández Secretary